Ipamorelin was tested in a multicenter, double-blind, placebo-controlled bowel-resection study. The median result numerically favored ipamorelin, but the difference was not statistically significant and the authors reported no significant key or secondary efficacy findings.
What the record shows
- 117 patients enrolled and 114 entered the safety and modified intention-to-treat analyses.
- Median time to a tolerated solid meal was 25.3 hours with ipamorelin and 32.6 hours with placebo.
- The primary comparison was not significant: p = 0.15.
Study record
A seven-hour numerical difference can look persuasive when detached from uncertainty. The prespecified statistical test is what determines whether the trial distinguished the groups beyond chance under its design; here it did not.
Results in context
Treatment-emergent adverse events were reported in 87.5% of the ipamorelin group and 94.8% of placebo participants. This was a postoperative inpatient population receiving a defined intravenous regimen, so it cannot be generalized to other routes or settings.
Preclinical receptor-selectivity work explains why ipamorelin was studied as a ghrelin-receptor agonist. Mechanistic plausibility did not guarantee a positive clinical endpoint.
What this study cannot answer
The trial was small and included heterogeneous surgical conditions.
The published protocol does not validate non-intravenous use or a catalog research lot.
Sources & editorial method
The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.
3 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- Randomized ipamorelin study after bowel resectionBeck DE, et al. International Journal of Colorectal Disease. 2014. PMID 25331030.
- Ipamorelin receptor-selectivity studyPreclinical pharmacology; PMID 9849822.
- Certain Bulk Drug Substances That May Present Significant Safety RisksU.S. FDA. Current compounding safety-information page.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
